CROI2024_2

REPRIEVE @ CROI 2024

The REPRIEVE Trial will present new findings in abstracts and during a symposium at the Conference on Retroviruses and Opportunistic Infections (CROI) 2024. The conference will take place in Denver, CO from March 3-6. See below for a listing of all REPRIEVE activities taking place during the conference.
Monday-Tuesday schedule2
Tuesday schedule continued2
Wednesday schedule2

  • Monday, March 4th00773 - Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE

    Time: 2:30 - 4:00 PM MST
    Presenting Author: Steve Grinspoon
    Session: Cardiovascular Disease Biomarkers - Poster Session-K1

  • Tuesday, March 5th00151 - Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE

    Time: 10:00 AM - 12:00 PM MST
    Presenting Author: Márton Kolossváry
    Session: Combating Complications of HIV - Oral-07

  • Tuesday, March 5th00152 - Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE

    Time: 10:00 AM - 12:00 PM MST
    Presenting Author: Kristine Erlandson
    Session: Combating Complications of HIV - Oral-07

  • Tuesday, March 5th00864 - Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among People With HIV

    Time: 2:30 - 4:00 PM MST
    Presenting Author: Katie Fitch
    Session: Factors Affecting Outcome of Acute COVID-19 - Poster Session-M2

  • Tuesday, March 5th00781 - Factors Affecting Risk of Major Adverse Cardiovascular Events among People with HIV in REPRIEVE

    Time: 2:30 - 4:00 PM MST
    Presenting Author: Markella Zanni
    Session: Cardiovascular Disease Trends and Risk Factor Modification - Poster Session-K2

  • Tuesday, March 5th00782 - Performance of the ACC/AHA Pooled Cohort Equation for Risk Prediction in the Global REPRIEVE Trial

    Time: 2:30 - 4:00 PM MST
    Presenting Author: Steve Grinspoon
    Session: Cardiovascular Disease Trends and Risk Factor Modification - Poster Session-K2

  • Wednesday, March 6thSymposium: Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

    Time: 4:00 PM - 5:30 PM MST
    "Overview of the REPRIEVE Trial" by Dr. Steve Grinspoon
    1) "Sex-Differences in Atherosclerotic CVD Risks and Mechanisms: Insights from REPRIEVE" by Dr. Markella Zanni
    2) "What's Next: Immune-Based Therapy for CVD and Comparison with the General Population" by Dr. Priscilla Hsue
    3) "Implications for Implementing CVD Risk Prevention Strategies for Low and Middle Income Countries" by Dr. Mpiko Ntsekhe
    Audience questions and discussionmoderated by Drs. Steve Grinspoon, Matthew Feinstein, and Franck Boccara.